Company news
Zhejiang Jianfeng Group Co. Ltd. Class A (SSE:600668) news
Zhejiang Jianfeng Group Co. Ltd. Class A news releases on 6ix. Latest, Sep 25, 2026: "Zhejiang Jianfeng Group Co., Ltd."Announcement on the Subsidiary's…
Press releases & updates
"Zhejiang Jianfeng Group Co., Ltd."Announcement on the Subsidiary's Receipt of the European CEP for Chemical API
September 24, 2026
"Zhejiang Jianfeng Group Co., Ltd."Announcement on Progress in Providing Guarantee for Controlled Subsidiary
September 22, 2026
"Zhejiang Jianfeng Group Co., Ltd."Announcement on the Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API
September 1, 2026
"Zhejiang Jianfeng Group Co., Ltd."Announcement on Resolutions of the 18th Meeting of the 12th Board of Directors
August 30, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on the Proposed Winning Bid of Subsidiary in the National Centralized Drug Procurement
August 3, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on Acquisition of Drug Registration Certificate by a Subsidiary
July 24, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 17, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on Expected Loss in Semi-annual Performance for 2026
July 14, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on Inclusion of the Subsidiary's Products in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025
July 2, 2026
"Zhe Jiang Jian Feng Group Co., Ltd."Announcement on Subsidiary Obtaining the Approval Notice for Drug Supplementary Application
June 30, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 25, 2026
Announcement on Overdue Financial Assistance Provided by a Subsidiary
June 17, 2026
Announcement on Resignation of Directors
May 19, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs
May 8, 2026
Report for Q1 2026
April 28, 2026
Announcement on Withdrawal of Drug Registration Application by the Subsidiary
April 24, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
April 20, 2026
Notice on Convening the 2025 Annual General Meeting
April 13, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
April 1, 2026
Announcement on Subsidiary Obtaining a Notice of Disapproval for the Drug Marketing Authorization Application
March 19, 2026
Earnings Preannouncement for 2025
January 27, 2026
Announcement on Withdrawal of Clinical Trail Application for Drug Registration by Subsidiary
January 15, 2026
Announcement on Subsidiary's Passing GMP Compliance Inspection for Drugs
December 23, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 21, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary
November 14, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 3, 2025
Announcement on Canceling the Board of Supervisors and Amending the "Articles of Association" and Some Internal Control Systems
October 29, 2025
Announcement on Progress in Changes in Equity Structure of Indirect Controlling Shareholder
September 29, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
September 26, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 19, 2025
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution
September 16, 2025
2025 Semi-annual Report
August 29, 2025
Indicative Announcement on Changes in Equity Structure of Indirect Controlling Shareholder
August 25, 2025
Announcement on Resolutions of the 11th Meeting of the 12th Board of Directors
August 15, 2025
Announcement on Adjusting Upper Limit of Shares Repurchase Price after Implementation Dividend Distribution for 2024
July 15, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 14, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 8, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
June 27, 2025
Announcement on By-election of Director
June 11, 2025
Announcement on Progress in Providing Guarantees for Wholly-owned Subsidiaries
June 9, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 22, 2025
Announcement on the Retirement and Resignation of Deputy General Manager
May 16, 2025
Report for Q1 2025
April 29, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders without Sales Limits Concerning Shares Repurchase
April 25, 2025
Announcement on Renewing Engagement of Accounting Firm
April 21, 2025
Announcement on Progress of Joint-stock subsidiary Tasly Pharmaceutical Group Co., Ltd. Selling Partial Equity
March 31, 2025
Announcement on Progress in Changing Equity Structure of Controlling Shareholder
January 24, 2025
Indicative Announcement on Changes in Equity Structure of Controlling Shareholder
January 21, 2025